12 results about "Sulfasalazine" patented technology

The invention belongs to the field of tumor nano immunotherapy, and particularly relates to a nano immunotherapeutic agent cooperating with I / II type photodynamic and multiple cell death and anti-tumor application of the nano immunotherapeutic agent. The invention successfully constructs the nanoparticles (HMB) capable of targeting mitochondria and simultaneously exciting the photodynamic effects of the type I and the type II. Based on in-vitro and in-vivo experiments of a system, it is verified that ferroptosis and pyroptosis can be effectively triggered through photodynamic therapy mediated by the combination of the HMB and a ferroptosis inducer sulfasalazine. The multi-mode cell death network constructed by combining HMB with salazosulfapyridine represents a novel promising cancer treatment method, so that a novel strategy with transformation potential is provided for solid tumor treatment; and an important theoretical and practical basis is provided for deeply understanding a tumor cell death mechanism and designing a new-generation intelligent photosensitizer system according to the death mechanism.

The utility model discloses a sulfasalazine synthetic equipment with stirring mixing mechanism relates to sulfasalazine synthetic field, including mixing jar body, break mechanism, break mechanism installs in mixing jar body top one side, lead screw, the lead screw, rotation is connected between mixing jar body inside top and bottom, wherein, the sliding sleeve is cooperated with the outside screw thread of lead screw, the connecting rod is fixed with the outside of sliding sleeve, the annular scraper is fixedly connected with connecting rod end, the annular scraper outside is attached to mixing jar body inner wall, break mechanism includes the discharge bin, the feed inlet is seted up in the middle of discharge bin top, and the device is pretreated to raw material through break mechanism, when the rotating shaft rotates, the mutual meshing of grinding teeth can carry out extrusion, shearing effect to raw material, realize the purpose of breaking, can make the powder that is relatively coarse become finer through the effect of grinding simultaneously.

The utility model discloses a kind of sulfasalazine fluidized bed with dust removal mechanism, it is related to fluidized bed technical field, including fluidized bed body, the side of fluidized bed body is connected with air inlet tank;The inside of the air inlet tank is slidably provided with filter screen, the inside of the air inlet tank is provided with fan, and fan is located at the side of filter screen close to fluidized bed body, the side of filter screen away from fluidized bed body is provided with rotating bar;When fan switches direction and backblows filter screen, rotating bar is driven to rotate by transmission assembly, impurities on filter screen are knocked loose, the side of filter screen close to fluidized bed body is provided with elastic component;The sulfasalazine fluidized bed with dust removal mechanism, by setting fan, rotating bar and transmission assembly and other structures, backblowing filter screen, realize the cleaning of impurities, while rotating bar hits filter screen, so that impurities are loose, ensure dust removal effect, improve the use efficiency of sulfasalazine fluidized bed.

The invention addresses radioresistance in cancer treatment involving radiotherapy and, in particular, limitations associated with the use of the drug sulfasalazine. Specifically, it provides a series of compounds for use as radiosensitizers in the treatment of cancers such as glioblastomas which are lethal and inherently resistant to radiotherapy. In one embodiment, the invention provides compounds of general formula (I), their stereoisomers and pharmaceutically acceptable salts for use as radiosensitizers in the treatment of cancer:wherein ring A is selected from optionally substituted phenyl, biphenyl and fluorenyl; each X is independently selected from: —C1-6 alkyl (preferably C1-3 alkyl, e.g. —CH3), —O—C1-6 alkyl (preferably —O—C1-3 alkyl, e.g. —OCH3), —S—C1-6 alkyl (preferably —S—C1-3 alkyl, e.g. —SCH3), —OH, —SH, —CO2R1 (where R1 is H or C1-6 alkyl, preferably C1-3 alkyl, e.g. —CH3), —SO2—C1-6 alkyl (preferably —SO2—C1-3 alkyl, e.g. —SO2—CH3), —SO2—NR2R3 (where R2 is H and R3 is optionally substituted phenyl), —NR4R5 (wherein R4 and R5 are independently selected from H, C1-6 alkyl (preferably C1-3 alkyl, e.g. —CH3), and —CO—C1-6 alkyl (preferably —CO—C1-3 alkyl, e.g. —CO—CH3), halogen (e.g. F, Cl or Br), and optionally substituted tetrazolyl; n is an integer from 0 to 5, preferably 0 to 2, e.g. 1 or 2; and denotes an E or Z double bond.

This invention discloses an alendronate-based chemical exchange saturation transfer magnetic resonance imaging (CELTMRI) probe, its preparation method, and its applications. It relates to the field of CELTMRI technology, and its key technical features are: the probe (Alen-FF-SSZ) is composed of an alendronate group (Alen), a phenylalanine-phenylalanine (FF) self-assembled group, and a sulfasalazine (SSZ) CEST MRI imaging unit. The specific molecular probe structure is shown below. This invention successfully developed an alendronate-based CEST MRI molecular probe, which has achieved CEST MRI imaging and treatment of osteosarcoma. This structure also has broad prospects for clinical translation.

The invention discloses application of enzyme powder prepared from bamboo shoots to improvement of ulcerative colitis, which comprises the following steps: S1, pretreatment culture and grouping: 72 C57BL / 6J male mice are adaptively fed for one week and then are divided into 6 groups, each group comprises 12 male mice, and the number of the male mice is 12; the method comprises the following steps: sequentially naming a normal control group (NC), a model group (DSS), a sulfasalazine group (SASP, 300 mg / kg), a square bamboo shoot enzyme low-dose group (CUJ-L), a square bamboo shoot enzyme medium-dose group (CUJ-M) and a square bamboo shoot enzyme high-dose group (CUJ-H); experimental data of mice show that the square bamboo shoot enzyme treatment can significantly improve colon shortening and DAI, improve weight loss and reduce the colitis symptom factor level; besides, the chimonobambusa quadrangularis ferment intervention improves the diversity and the structure of intestinal bacteria, the composition of intestinal microbiota is remodeled, the abundance of Firmicite gate is improved, and the abundance of Proteobacteria and Verrucomicrobiota, including Escherichia-Shiga, Akkermansia and other species, is reduced, and the application of the chimonobambusa quadrangularis ferment intervention in the preparation of the chimonobambusa quadrangularis ferment intervention in the preparation of the chimonobambusa quadrangularis ferment intervention in the preparation of the chimonobambusa quadrangularis ferment intervention in the preparation of the chimonobambusa quadrangularis ferment is promoted. The intestinal metabolite and the intestinal flora have a close relationship; according to the method, 32 key metabolites are screened out through cecum metabolite analysis, and the key metabolites mainly relate to a Propionate metabolite metabolic pathway; the result shows that the square bamboo shoot enzyme has the potential of treating colitis.

The invention belongs to the technical field of biological medicines, and discloses application of a deep-sea butyrolactone compound in preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The butyrolactone compound disclosed by the invention is specifically 5-acetyl-3-hydroxy-4-(4-hydroxyphenyl)-5-[4-methyl-3-(3-methylbutyl-2-ene-1-yl) benzyl] furan-2 (5H)-ketone, and the structural formula of the butyrolactone compound is shown in the description. It is proved for the first time that the butyrolactone compound has the activity of remarkably improving the inflammatory bowel disease, the body weight, defecation, intestinal length and intestinal weight of a mouse with the inflammatory bowel disease induced by DSS are remarkably improved, and the effect of the butyrolactone compound is superior to that of a positive drug salazosulfapyridine (SASP). The invention provides the application of the butyrolactone compound or the derivative thereof or the pharmaceutically acceptable salt thereof in preparing the medicine for preventing and / or treating the inflammatory bowel disease, and provides a new medicine for treating the inflammatory bowel disease, so that the butyrolactone compound has a wide application prospect.

The application relates to the medical technical field, in particular to application of sulfasalazine in preparation of a medicine for treating primary biliary cholangitis (PBC) which is poorly responsive to ursodeoxycholic acid (UDCA), aiming at the clinical problem that about 40% of PBC patients are poorly responsive to the first-line drug UDCA, have high disease progression risk and limited second-line treatment options, and providing a new treatment use of the mature drug sulfasalazine. Through prospective clinical research, it is confirmed that, on the basis of UDCA standard treatment, combined use of sulfasalazine (1.5g / day, a treatment course of 48 weeks) can significantly improve liver biochemical indexes of UDCA non-responders, including alkaline phosphatase and gamma-glutamyltransferase, and 62.5% of the patients reach composite biochemical response. The application provides a new, effective, safe and highly accessible second-line treatment strategy for PBC patients who are poorly responsive to UDCA, and has a good clinical application prospect.

The invention belongs to the technical field of medicinal chemistry, and particularly discloses a platinum (IV) prodrug with ferroptosis and apoptosis induction effects as well as a preparation method and application of the platinum (IV) prodrug. According to the invention, a novel platinum (IV) compound with a ferroptosis induction effect is developed based on platinum (IV) prodrugs of salazosulfapyridine, cis-platinum and carboplatin; the platinum (IV) prodrug disclosed by the invention shows excellent anti-proliferative activity to cisplatin-sensitive and drug-resistant triple negative breast cancer cells, and compared with cisplatin, the platinum (IV) prodrug has lower activity to a normal mammary gland cell line (MCF-10A). Accumulation of reactive oxygen species (ROS) in cells can be improved by inducing DNA damage, and a mitochondrial dependent approach is activated to induce apoptosis. Meanwhile, accumulation of lipid peroxide can be remarkably promoted, xCT and GPX4 levels are reduced, and mitochondrial morphological change is induced to stimulate ferroptosis; in vivo, the cis-platinum (IV) prodrug shows strong anti-tumor activity in an MDA-MB-231 / CDDP xenograft model, and the cis-platinum (IV) prodrug has strong anti-tumor activity; the platinum (IV) prodrug has a potential application prospect in targeted therapy of triple negative breast cancer.

This utility model discloses an energy-saving sulfasalazine wastewater treatment device, relating to the field of wastewater treatment equipment. It includes a first treatment tank and a second treatment tank, which are vertically arranged. An upper collection tank and a lower collection tank are respectively connected vertically inside the first and second treatment tanks, and are connected by a connecting rope and pulley. The lower collection tank is heavier than the upper collection tank. Both the upper and lower collection tanks have filter screens at their bottom ends. After the sediment in the wastewater settles, the wastewater is discharged from the first treatment tank and flows into the second treatment tank. The downward discharge of wastewater causes the collection tank to descend, thereby pulling the upper collection tank upward. This causes the collection tank to lift the sediment in the wastewater, facilitating subsequent processing. The wastewater utilizes gravity to treat the sediment, requiring no additional energy, making it environmentally friendly and energy-saving.

A method for producing an enriched population of human MSCs, comprising culturing isolated MSCs in xeno-free medium to at least 80% confluence, followed by treatment with a priming agent: erastin, sulfasalazine, or a combination thereof, to produce expanded MSCs positive for CD73, CD90, and CD105. A method is also provided for treating or preventing tissue damage or dysfunction, comprising the aforementioned method involving priming of human MSCs with a low dose of a priming agent. Further, a composition comprising primed MSCs and a cell culture medium system including the priming agent. Accordingly, the low-dose FINs offer a novel approach as a priming agent in large-scale stem cell expansion process. And the primed MSCs after low-dose FINs treatment could be applied to transplantation into oxidative and inflammatory microenvironments.

The application discloses application of Jatrophulang fruit or stem extract in preparation of a medicine for treating ulcerative colitis. The Jatrophulang fruit or stem extract is an ethanol extract of Jatrophulang fruit or stem. The Jatrophulang fruit or stem extract provided by the application can significantly improve colitis inflammation of a mouse induced by dextran sulfate sodium, reduce a disease activity index of the mouse, obviously improve a shortened colon length of the mouse caused by modeling, significantly improve a survival rate of the mouse with ulcerative colitis, and significantly reduce inflammatory cell infiltration of colon tissue, and has a significant anti-ulcerative colitis activity, and the effect is equivalent to that of a positive medicine, i.e., sulfasalazine, and has a good application prospect in preparation of a medicine for treating inflammatory bowel disease.